Elicera Therapeutics AB: Advancing Immuno-Oncology with Innovative Therapies

Elicera Therapeutics AB, a clinical-stage immuno-oncology company headquartered in Gothenburg, Sweden, continues to make strides in the development of cell and gene therapies aimed at immune-based cancer treatments. The company, listed on the Swedish Stock Exchange, has been focusing on innovative solutions to address the complex challenges of cancer treatment, serving a global customer base.

As of May 8, 2025, Elicera’s stock closed at 5.12 SEK, reflecting a stable performance in the market. The company’s shares have experienced significant fluctuations over the past year, with a 52-week high of 5.18 SEK and a low of 0.852 SEK on May 14, 2024. Despite these variations, Elicera maintains a market capitalization of 203,606,598 SEK, underscoring its position as a key player in the healthcare sector.

Elicera’s primary focus is on developing cutting-edge cell and gene therapies that harness the power of the immune system to combat cancer. By leveraging advanced scientific techniques, the company aims to provide more effective and personalized treatment options for patients worldwide. Their commitment to innovation is evident in their ongoing research and development efforts, which are central to their mission of transforming cancer care.

For more detailed information about Elicera Therapeutics AB’s offerings, initiatives, and future plans, interested parties can visit their official website at www.elicera.com . The company continues to engage with the scientific community and investors, sharing updates on their progress and exploring new opportunities for growth and collaboration in the field of immuno-oncology.